Untitled

Abstract

Even with the significant advancements in medical and therapeutical fields, finding efficient anti-diabetic and anti-oxidative entities is of high significance in the recent era. New coumarin-disubstituted benzene conjugates were prepared to evaluate their antidiabetic and antioxidative effects. The prepared conjugates (MT0-MT7) were characterized utilizing various analytical techniques, including FTIR, UV-Vis, 1 H-NMR, and 13 C-NMR. Also, the drug-likeness properties of conjugates were assessed in-silico. The antidiabetic effect of the prepared conjugates was estimated in-vitro based on their inhibitory impact on porcine α-amylase and yeast α-glucosidase enzymes; whereas their antioxidative effect was appraised in-vitro based on their snaring impact on hydroxide and DPPH radicals. The findings of evaluating these effects demonstrated that the MT2 and MT3 conjugates had a prominent antidiabetic effect related to the standard. In addition, the MT0 conjugate showed a distinct antioxidative effect comparable to that of the standard. Thus, MT2, MT3, and MT0 conjugates could be used as scaffolds to develop a new class of antidiabetic and antioxidative entities. Moreover, the in-silico analysis revealed that the majority of the prepared conjugates had convenient drug-likeness properties for the oral drug-delivery system.

Untitled

“…This rule importance in identifying clinically meaningful pharmacokinetic drug-likeness still seems to be valuable today. Calculations of the selective compounds 1-20 (COX-I and COX-II) [23,24] are indicated in (Table 3). Nowadays, it is standard practice to use computational results in experimental research on orbitals and surfaces in 3 dimensions because modern DFT simulation algorithms for solid-state calculations can calculate a wide range of structural, chemical, spectroscopic, and thermodynamic properties.…”

Untitled

“…Thus, new ways were required to maintain glycaemic control while avoiding hypoglycaemia and other adverse consequences [4]. As a result of recent advancements in this sector, new antidiabetics such as incretin mimics, amylin analogues, GLP analogues, dipeptidyl peptidase-4 (DPP-4) inhibitors, PPAR agonists, and PPAR antagonists have been developed [5]. Using DPP-4 inhibitors to treat type 2 diabetes is a novel and intriguing technique.…”